Is SS-31 (elamipretide) FDA-approved? Yes - for Barth syndrome, not for aging

TL;DR

• Yes - on 19 September 2025 the FDA granted accelerated approval to FORZINITY (elamipretide HCl), from Stealth BioTherapeutics.
• The indication is Barth syndrome only - one ultra-rare X-linked genetic disorder, one muscle-strength endpoint, one defined population.
• The file was rejected first - a complete response letter in May 2025, resubmission on 15 August, FDA acceptance on 21 August.
• TAZPOWER missed its primary endpoints - 12 genetically confirmed patients; the strength gain was not seen in the randomised phase and emerged only in open-label extension, which 10 of the 12 entered and 8 continued through week 168.
• Accelerated approval means confirmatory evidence is still owed - clinical benefit is anticipated rather than verified, and the status can change.
• Nothing here speaks to ageing - outside Barth syndrome, elamipretide has repeatedly missed primary endpoints in mitochondrial myopathy, dry AMD and heart failure.

Updated September 2026: adds the trial's attrition through the open-label extension (10 of the 12 randomised patients entered it), notes that expanded access continues for children below the approval's weight threshold, and records FDA warning letters issued to online sellers in August 2026 that list elamipretide among the substances offered, reported as enforcement activity only.

Updated August 2026: corrects the regulatory timeline (NDA resubmitted 15 August 2025 after a May 2025 complete response; approval 19 September 2025), and restores the verified one-hour timescale for the aged-mouse finding with its primary citation.

---

The answer, in full

The question usually arrives second-hand. Someone has been told there is now an FDA-approved mitochondrial peptide, and is trying to establish whether that is true. It is true - and it does not mean what it is usually made to mean.

The specifics, all of which matter:

• What: FORZINITY (elamipretide HCl), from Stealth BioTherapeutics.
• When: 19 September 2025.
• How it got there: the FDA issued a complete response letter in May 2025. Stealth resubmitted its New Drug Application on 15 August 2025, seeking accelerated approval on knee-extensor muscle strength as recommended by the agency, and including a protocol for a post-marketing trial to confirm clinical benefit. The FDA accepted the resubmission for review on 21 August 2025.
• Pathway: Accelerated approval - meaning approval on an endpoint reasonably likely to predict clinical benefit, with confirmatory evidence still owed. See what accelerated approval actually means.
• Indication: Barth syndrome, an ultra-rare X-linked genetic mitochondrial disorder.
• Endpoint: to improve muscle strength, supported by an intermediate clinical endpoint - knee-extensor muscle strength.
• Population: adult and paediatric patients weighing at least 30 kg. That weight figure is a patient eligibility criterion in the approved indication, not a dose - it defines who the approval covers. Children below the threshold are outside the approval, and expanded access continues for them; that is a regulated, physician-directed mechanism for an unapproved population, not a route of availability for anyone else.

Read that list once more as a unit, because the phrase "FDA-approved SS-31" collapses all of it into two words and discards the rest. An FDA approval is indication-specific, population-specific and endpoint-specific, simultaneously. This one is all three, narrowly. It is also worth noticing that the approval followed a rejection - this was not a straightforward file, and the pathway it eventually took was the one reserved for cases where conventional evidence is not obtainable.

If you have arrived here trying to work out how SS-31 compares with the other compounds discussed in this space, the mechanism-by-mechanism comparison is in SS-31 vs MOTS-c vs SLU-PP-332 - that article covers what each molecule actually does. This one covers what the approval does and does not establish.

What Barth syndrome is, and how many people have it

Barth syndrome is an ultra-rare, X-linked, life-limiting genetic disorder. It is caused by mutations in the tafazzin (TAZ) gene. Tafazzin is an enzyme responsible for remodelling cardiolipin - a distinctive phospholipid concentrated in the inner mitochondrial membrane, where it is essential to that membrane's structure and to the function of the respiratory machinery embedded in it.

When TAZ is mutated, mature cardiolipin is reduced and abnormal intermediates accumulate. The inner mitochondrial membrane loses structural integrity, and the consequences are systemic: cardiomyopathy, skeletal muscle weakness, neutropenia, growth delay and exercise intolerance are characteristic features. Because the gene sits on the X chromosome, the condition affects primarily males.

Roughly 150 individuals are known and diagnosed in the United States. That figure should be read precisely: it is a count of diagnosed patients, not a prevalence estimate. The true number of people with the condition is likely higher, since ultra-rare disorders are systematically under-diagnosed - the published registry literature notes that fewer than 200 living males are known worldwide while evidence accumulates that the disorder is substantially under-recognised, and that a meaningful minority of patients are not diagnosed until adulthood. The count is not the output of a population survey. Some press and sponsor materials present the same number as an estimate of how many people are affected; the diagnosis-count reading is the more conservative one and the one used here.

But the order of magnitude is the point. This is a disorder affecting a group small enough to be individually known to the clinical community.

That context is essential to reading the approval fairly. It explains why the evidence base looks the way it does, and it explains why the FDA acted on that evidence base rather than demanding more.

What the approval was actually based on

Elamipretide is a small, cell-permeable peptide. Unlike most peptide therapeutics, it does not act on a cell-surface receptor. It crosses the cell membrane, concentrates at the inner mitochondrial membrane, and binds reversibly to cardiolipin. The proposed effect is structural: stabilising the phospholipid that holds the inner membrane's architecture together. In a disease defined by defective cardiolipin, that is a directly targeted mechanism rather than a general metabolic one.

The TAZPOWER evidence, stated plainly

The approval rested on TAZPOWER, a randomised, double-blind, placebo-controlled crossover trial in 12 genetically confirmed patients.

Here is the part that deserves to be stated without softening: the trial did not meet its primary endpoints - neither distance walked on the six-minute walk test nor total fatigue score improved significantly against placebo - and knee-extensor muscle strength gains were not observed during the randomised phase. The improvement that supported the approval emerged during the open-label extension. Of the 12 patients enrolled in the randomised trial, 10 entered the extension and 8 continued through week 168.

That is a genuinely limited evidence base by the standards applied to most drugs, and the limitation is material rather than technical. The randomised comparison - the part of the trial designed to isolate drug effect from everything else - did not show the strength benefit at all. The endpoint the approval rests on was met only in open-label follow-up, where patients and investigators know who is receiving what, where there is no concurrent control group to account for natural history, learning effects on a strength assessment, or expectation, and where the cohort shrinks as it goes: twelve randomised, ten into the extension, eight to week 168. A result that appears only after the blind comes off, in a group that small and attriting, is the weakest form the supporting evidence for an approval can take. It should be read as the reason a confirmatory trial is owed, not as a detail.

Both things can be true at once, and both should be said:

• This is defensible for an ultra-rare disease with no alternative therapy. You cannot run a large randomised trial in a population of roughly 150 diagnosed individuals. Requiring one would mean requiring that no therapy ever be approved. The accelerated approval pathway exists precisely for situations where waiting for conventional evidence has an unacceptable human cost, and a life-limiting disorder with no approved treatment is close to the paradigm case.
• Readers deserve to know it rather than be sold "FDA-approved" as a proxy for "proven". The two-word phrase carries an implication of demonstrated efficacy that this evidence package does not support, and would not claim to.

Accelerated approval means confirmatory evidence is still owed. The clinical benefit is anticipated on the strength of the endpoint used, not verified. Stealth's resubmission included a protocol for a post-marketing confirmatory trial. That obligation is a live one, and the approval's status can change depending on what the confirmatory work shows.

The rest of the elamipretide trial record

Fairness in the other direction also requires noting what has happened outside Barth syndrome. Elamipretide has been through several larger trials in other conditions and has repeatedly failed to meet its primary endpoints, including in primary mitochondrial myopathy, in dry age-related macular degeneration, and in heart failure. Those failures are covered in more detail in SS-31 vs MOTS-c vs SLU-PP-332.

There is a coherent reading of that overall pattern: a molecule that stabilises cardiolipin may do the most where cardiolipin is genuinely, structurally, genetically defective, and comparatively little where the mitochondria are broadly intact. That reading is a hypothesis consistent with the data, not an established finding. But it is the opposite of the reading implied by "FDA-approved mitochondrial peptide."

Approved for a rare disease is not evidence it works for aging

This section is the reason the article exists, so it will not be hedged.

Nothing in the FORZINITY approval package constitutes evidence that elamipretide improves energy, fatigue, exercise capacity, healthspan or any aging-related outcome in people without Barth syndrome. Not weak evidence. Not preliminary evidence. No evidence, because that study was not the study that was done. An approval for a rare mitochondrial disease is a statement about one disease. It is not evidence about aging, and "approved for X" is never evidence that something works for Y.

The reasoning is structural rather than sceptical:

• The population studied was 12 people with a specific confirmed genetic mutation. Findings in a genetically defined ultra-rare disease population do not generalise to people without that mutation. The mechanism being corrected is a mutation-driven cardiolipin deficiency. In someone without the mutation, the deficiency being targeted is not present in the same form.
• The endpoint studied was knee-extensor muscle strength. Not fatigue. Not perceived energy. Not aerobic capacity. Not any measure of aging.
• The pathway used was accelerated approval. Even for the approved indication, clinical benefit is anticipated rather than verified.
• The wider trial record in non-Barth populations is a record of missed primary endpoints. Where elamipretide has been tested in larger, non-Barth populations, it has largely not met the endpoints set.

That last point is worth dwelling on. The situation is not that the aging question is merely unstudied. It is that in the adjacent conditions where the drug has been tested in people whose mitochondria are impaired for non-Barth reasons, it has repeatedly not delivered. That is more informative than silence, and it points in the less exciting direction.

On the phrasing. This is correctly described as the first FDA-approved therapy for a mitochondrial disease. That is an accurate and genuinely notable statement - it means a category of disease that previously had no approved treatment now has one. It is a narrower statement than the broader claim sometimes made in coverage and in sponsor materials, which frames elamipretide as the first therapeutic of its kind to reach approval at all. This article does not make that broader claim, and the distinction survives the temptation to round up.

The mouse data, held separately

Preclinical work on elamipretide in aged animals is frequently cited in longevity content, usually without the species attached. It is worth reading, and it is worth reading as what it is.

In aged mice, elamipretide has been reported to restore skeletal-muscle mitochondrial energetics - maximal ATP production, the coupling of oxidative phosphorylation, and cellular energy state - to levels seen in young animals, measured one hour after a single injection, with muscle also more fatigue-resistant at that same one-hour timepoint (Siegel et al., Aging Cell, 2013). The speed is mechanistically coherent: the compound reaches the inner mitochondrial membrane and binds cardiolipin without requiring changes in gene expression, so a fast functional change does not require anything to be transcribed or built.

Three qualifications, all of which belong on the page:

1. This is mouse data. Aged mice are not aging humans. Mouse skeletal muscle physiology, mouse mitochondrial turnover and mouse lifespan differ from ours in ways that have repeatedly defeated compounds that looked excellent in rodents. The species is not a footnote. The same paper also found no observable effect in young mice, which is itself a reminder of how specific the finding is.
2. The measured outcomes are physiological, not clinical. ATP production and fatigue resistance measured by spectroscopy and in muscle preparations are mechanistic readouts. They are not "the mice felt better" and they are certainly not "people would feel better."
3. The clinical translation has already been attempted and has largely not succeeded. The human trials in non-Barth populations described above are, in effect, the test of whether this preclinical promise translates. So far, in those settings, it mostly has not.

The honest summary of the mouse data is: a real, well-documented, mechanistically coherent preclinical finding in aged animals, which has not translated into positive clinical results outside the one ultra-rare genetic disease where the underlying defect is precisely the thing the molecule addresses. A fast effect in a mouse is a fast effect in a mouse.

The supply-chain distinction

The approved pharmaceutical product and a same-named research chemical are not the same thing, and conflating them is the most consequential error available on this topic.

FORZINITY is a specific formulation, manufactured under current Good Manufacturing Practice, with an established identity, purity and stability profile, released against specifications, and distributed through a regulated prescription supply chain for a named indication.

A substance sold under the name "SS-31" or "elamipretide" outside that chain shares the name. It does not thereby share the manufacturing standard, the identity and purity assurance, the stability data, the regulatory status, or the accountability if something is wrong with the vial. Those are properties of the product and its supply chain, not of the molecule name printed on a label.

The FDA approved a product. It did not approve a molecule in the abstract, and it certainly did not approve any particular vial of anything. "The FDA approved elamipretide" and "this is an FDA-approved product" are different claims, and the first is routinely used to imply the second.

The regulator has since acted on that conflation

There is a dated data point on this, and it belongs here.

In August 2026 the FDA issued warning letters to online sellers offering unapproved substances, and elamipretide appears among the compounds listed in that enforcement action - the letters are dated 24 August 2026 and were posted on 1 September 2026.

That is recorded here as enforcement activity and nothing else. It establishes that a market in the name exists and that the agency regards selling it as unlawful; it says nothing about the molecule's biology, it does not alter the approval, and it is not a comment on the approved product or its sponsor. This article names no seller, describes no supply route, and takes no position on where anything is obtainable - the presence of an enforcement action is precisely the reason not to treat that as a question worth answering. A compound being the subject of a warning letter is a reason for less confidence in what is being sold under its name, not more.

Where this leaves someone interested in mitochondrial function

If the underlying interest is mitochondrial function rather than this specific molecule, the useful move is to go back to mechanism rather than to a shopping list.

Mitochondrial decline with age is not one process. It includes reduced mitochondrial content, impaired quality control and clearance of damaged organelles, altered signalling from mitochondria to the nucleus, and structural degradation of the inner membrane - of which cardiolipin damage is one component. Different interventions in this space address entirely different parts of that picture. Elamipretide targets membrane structure. Compounds acting through AMPK and downstream biogenesis signalling target organelle production. Others target clearance. These are not interchangeable, and none of them is a general-purpose fix.

The mechanism map is set out in mitochondria and aging, the comparison across the main peptide candidates in SS-31 vs MOTS-c vs SLU-PP-332, and the specific case of exercise-associated signalling in MOTS-c and the exercise-mimetic story.

This article makes no selection recommendation and offers no comparison of what anyone should consider using. It sets out one regulatory fact accurately, which is a narrower and more useful job.

Frequently asked questions

Can I get it? FORZINITY is a prescription product approved for a specific, genetically confirmed, ultra-rare diagnosis, and it is distributed accordingly. This article does not discuss access routes, and there is no legitimate consumer pathway to it for energy, fatigue or aging - because there is no approved indication for those, and no evidence base supporting them. If you have or suspect Barth syndrome, that is a conversation for a clinician with expertise in inherited metabolic disease, not a question this page can answer.

Is it available off-label? This article does not describe off-label access, availability or acquisition for any purpose. What can usefully be said is the evidence position: outside Barth syndrome, elamipretide has repeatedly not met its primary endpoints in the larger trials where it has been tested, and there is no clinical evidence base supporting use for aging or energy. Any question about therapy for a specific individual is a matter for that person's own physician, working from their diagnosis rather than from a molecule's reputation.

Is SS-31 the same as MOTS-c? No, and they are not close. SS-31 (elamipretide) is a synthetic four-amino-acid peptide that concentrates at the inner mitochondrial membrane and binds cardiolipin - a structural intervention on the membrane itself. MOTS-c is a peptide encoded within mitochondrial DNA that acts as a signalling molecule, principally through AMPK, nudging the cell towards making more and better mitochondria. Repairing existing structure and signalling for new production are different jobs. The full comparison, including SLU-PP-332, is in SS-31 vs MOTS-c vs SLU-PP-332.

What does "the first FDA-approved therapy for a mitochondrial disease" mean precisely? It means that the category of inherited mitochondrial diseases, which previously had no FDA-approved treatment, now has one - for one specific disease in that category, on one endpoint, in one defined population, under accelerated approval with confirmatory evidence still owed. It is a real milestone for a patient community that had nothing. It does not mean mitochondrial disease in general is now treatable, it does not support any broader "first of its kind" framing, and it does not mean anything at all about mitochondrial function in people without a mitochondrial disease.

Does the fast effect in mice mean anything for people? Not on its own. The aged-mouse finding is real and well documented - mitochondrial energetics and fatigue resistance improved within an hour of a single injection - but it is a physiological readout in a rodent, and the same paper found no effect in young mice. The human trials in populations without Barth syndrome are the test of whether that translates, and so far they have mostly not met their endpoints.

Related reading

• SS-31 vs MOTS-c vs SLU-PP-332 - what each molecule actually does, mechanism by mechanism, and the full elamipretide trial record
• What accelerated approval actually means - surrogate endpoints, the confirmatory obligation, and why "approved" is not "proven"
• MOTS-c and the exercise-mimetic story - the signalling side of mitochondrial biology, and where its evidence actually sits
• Mitochondria and aging - the mechanism map that makes this whole category legible
• How a mitochondrial diagnosis is actually made - why "mitochondrial dysfunction" and mitochondrial disease are not the same thing

Part of The Complete Guide to Mitochondria & Longevity.

Educational content, not medical advice. This article contains no doses, schedules or protocols, and describes no route of access to any product. FORZINITY is approved under the FDA's accelerated approval pathway for a single indication in a defined population; confirmatory evidence remains outstanding, and approval status can change. Approval for one indication is not evidence of effect in any other. Any decision about therapy is a physician-directed one, made from a diagnosis. Claims for the Malaysian market are subject to MAB requirements.

If mitochondrial function is what you actually came here about, the useful next step is a mechanism conversation, not a molecule. Vivre Labs publishes the evidence tier alongside every compound it discusses and routes questions like this to a consult rather than a product page. Book a consult to discuss what is measurable, what is modifiable, and what is currently unproven - Telegram.

References

• US Food and Drug Administration, accelerated approval of FORZINITY (elamipretide hydrochloride), Stealth BioTherapeutics, 19 September 2025 - to improve muscle strength in adult and paediatric patients with Barth syndrome weighing at least 30 kg.
• Stealth BioTherapeutics: FDA complete response letter, May 2025; New Drug Application resubmitted 15 August 2025 seeking accelerated approval on knee-extensor muscle strength as an intermediate clinical endpoint, with a post-marketing confirmatory trial protocol included; FDA acceptance of the resubmission announced 21 August 2025.
• TAZPOWER (NCT03098797): randomised, double-blind, placebo-controlled crossover trial of elamipretide in 12 genetically confirmed patients with Barth syndrome, with open-label extension; primary endpoints (six-minute walk distance and total fatigue score) not met against placebo; knee-extensor muscle strength gains not observed during the randomised phase, with improvement emerging during the open-label extension - of 12 patients enrolled in the randomised trial, 10 entered the extension and 8 continued through week 168.
• Expanded access continues for children below the weight threshold specified in the approved indication; the threshold is an eligibility criterion for the indication, not a dosing instruction.
• US FDA warning letters to online sellers of unapproved substances, letters dated 24 August 2026 and posted 1 September 2026, listing elamipretide among the compounds offered. Cited as enforcement activity only; no seller, source or supply route is identified here, and the action does not affect the approval status of the approved product.
• Barth syndrome clinical and genetic characterisation: X-linked mutations in the tafazzin (TAZ) gene, reduced mature cardiolipin, impaired inner mitochondrial membrane structure and function; approximately 150 individuals known and diagnosed in the United States (a diagnosis count, not a prevalence estimate); Barth Syndrome Foundation registry literature on under-diagnosis and delayed diagnosis.
• Siegel MP, et al. Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice. Aging Cell 2013;12(5):763–771. Single-dose treatment in aged mice restored in vivo skeletal-muscle mitochondrial ATP production, P/O coupling and PCr/ATP to young levels one hour after injection, with muscle more fatigue-resistant in situ at one hour; no observable effect in young mice.
• Mitchell W, et al. Characterisation of elamipretide binding to cardiolipin at the inner mitochondrial membrane. Journal of Biological Chemistry, 2020.
• Elamipretide clinical programme outside Barth syndrome: MMPOWER-3 in primary mitochondrial myopathy (co-primary endpoints not met), and trials in dry age-related macular degeneration and heart failure that did not meet primary endpoints.
• US FDA, "Accelerated Approval" and "Expedited Programs for Serious Conditions - Drugs and Biologics", on approval via endpoints reasonably likely to predict clinical benefit and the associated confirmatory-evidence obligation.